Alendronate Sodium Tablet
Product Images NDC 69097-223

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 69097-223). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 01

Chemical structure diagram of alendronate sodium showing two phosphonate groups attached to a central carbon with an amino group and three water molecules (trihydrate) associated.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 02

A line graph showing the cumulative incidence of hip fractures over 36 months in a three-year study comparing Alendronate Sodium and placebo treatments among patients with radiographic vertebral fracture at baseline. The graph shows time in months on the x-axis and cumulative incidence percentage on the y-axis, with Alendronate Sodium having a lower cumulative incidence than placebo throughout the study duration.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 03

A bar chart titled 'Osteoporosis Treatment Studies in Postmenopausal women: Increase in BMD (Bone Mineral Density) with Alendronate Sodium 10 mg/day at Three Years.' It compares mean percentage increases in BMD relative to placebo at lumbar spine, femoral neck, and trochanter sites between U.S. and multinational study populations, with error bars representing standard error.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 04

A figure showing two line graphs comparing the effect of Alendronate Sodium 10 mg daily versus placebo on lumbar spine bone mineral density (BMD) percent change from baseline over 36 months. One graph presents data from a US study, and the other from a multinational study, illustrating mean percent BMD changes with error bars over time in months.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 05

Two bar graphs comparing mean percentage change in bone mineral density (BMD) from baseline in postmenopausal women over 2-year and 3-year osteoporosis prevention studies. Data is shown for lumbar spine, femoral neck, trochanter, and total body, contrasting Alendronate Sodium 5 mg/day versus placebo.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 06

A bar chart depicting the mean percentage increase in bone mineral density (BMD) relative to placebo after one year of Alendronate Sodium 5 mg/day treatment in glucocorticoid-treated patients. The chart compares results for the U.S. cohort and a multinational cohort at three anatomical sites: lumbar spine, femoral neck, and trochanter.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 07

A line graph showing the effect of Alendronate Sodium 40 mg/day compared to Placebo and Etidronate 400 mg/day on serum alkaline phosphatase levels in Paget's Disease of Bone over 6 months. The y-axis represents mean percent change from baseline, and the x-axis represents time in months. Data points for four groups with sample sizes are shown, including multinational and U.S. studies of Alendronate Sodium.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 08

Alendronate Sodium 35 mg oral tablets, USP, in blister packaging labeled for once weekly use. The label includes instructions for tablet removal from the blister, storage conditions, and dispensing information. Manufactured by Cipla USA Inc., with 1 blister of 4 tablets contained in the package.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 09

Packaging label for Alendronate Sodium Tablets USP, 70 mg, oral tablet, manufactured by Cipla USA Inc. The label indicates a once weekly dosage with instructions for removing tablets from the blister card. The label also includes storage conditions, medication guide advisory, barcode, and NDC number 69097-224-16.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.